Germany | Bayern

Zurück zur Suche

Internationale Partnersuche

Innovation & Technologie Anfrage

Virtual screening technology based on deep learning using big data

Country of Origin: South Korea
Reference Number: TRKR20181107001
Publication Date: 7 November 2018

Summary

A Korean pharmaceutical company is active in research and development of new drugs based on natural products and orphan disease through virtual screening technology on the basis of AI. The technology that the company wants to develop by cooperation is virtual screening technology based on deep learning using big data. The type of partnership is commercial agreement with technical assistance.

Description

A Korean company is a pharmaceutical-based and established in 2018.

The company specializes in development of new drugs of orphan diseases with a use of virtual screening technology. The company comes up with the idea of the new drugs based on natural products due to treatment of orphan diseases and senile diseases in a short period of time, which result in high quality of life eventually.

The company is planning on development of new drugs with improved functions that would enable to be applied on orphan disease and general diseases with partners under commercial agreement with technical assistant.

Expertise sought

Reducing the time of development of new drugs as well as reducing the risk of failure result in costs for research and development ultimately. As technology is a competitive advantage, it will lead the world pharmaceutical market. Also, pharmaceutical and bio-pharma and engineering technology based on IT software are fused to create new values, which could provide new industries and jobs eventually.

Stage Of Development

Available for demonstration

Requested partner

- Type of partner: Technological SME or large enterprise is preferable with experience in Big data(AI)

- Specific area of activity of the partner: Any partner specialized in the technology for screening technology based on deep learning using big data

- Task to be performed: Partners should engage in pharmaceutical companies or research institute or specialize in virtual screening technology in the basis of deep-learning to develop new drugs on orphan disease under commercial agreement with technical assistance.

Kooperationsanfrage stellen